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Adipose tissue is acknowledged as an endocrine organ that releases bioactive factors termed adipokines. Visfatin was initially
identified as a novel adipokine with insulin-mimetic properties in mice. This adipokine was identical to two previously described
molecules, namely, pre-B cell colony-enhancing factor (PBEF) and the enzyme nicotinamide phosphoribosyltransferase (Nampt).
Enhanced circulating visfatin/Nampt levels have been reported inmetabolic diseases, such as obesity and type 2 diabetes.Moreover,
visfatin/Nampt circulating levels correlate with markers of systemic inflammation. In cardiovascular diseases, visfatin/Nampt was
initially proposed as a clinical marker of atherosclerosis, endothelial dysfunction, and vascular damage, with a potential prognostic
value. Nevertheless, beyond being a surrogate clinical marker, visfatin/Nampt is an active player promoting vascular inflammation,
and atherosclerosis. Visfatin/Nampt effects on cytokine and chemokine secretion, macrophage survival, leukocyte recruitment by
endothelial cells, vascular smooth muscle inflammation and plaque destabilization make of this adipokine an active factor in the
development and progression of atherosclerosis. Further research is required to fully understand the mechanisms mediating the
cellular actions of this adipokine and to better characterize the factors regulating visfatin/Nampt expression and release in all these
pathologic scenarios. Only then, we will be able to conclude whether visfatin/Nampt is a therapeutical target in cardiometabolic
diseases.
1. Introduction
Theadipose tissue (AT) is no longer considered a triglyceride-
storing depot but a real endocrine organ that synthesizes
and secretes a wide range of diverse bioactive factors, called
adipokines. These adipokines can act locally within the
adipose tissue, but can also trigger an effect on distant
organs or tissues through their release to the systemic
circulation. Adipokines comprise cytokines and chemokines,
such as tumor necrosis factor- (TNF-) 𝛼, interleukins (IL),
or monocyte chemotactic protein-1 (MCP-) 1, vasoactive and
coagulation factors, such as angiotensinogen or plasminogen
activator inhibitor-1, (PAI-1), and proteins more specifically
secreted by the adipose tissue, such as leptin or adiponectin.
In the last years, the number of the adipokines has notably
increased with novel adipokines such as visfatin/Nampt,
resistin, apelin, or dipeptidyl peptidase-4 (DPP-4) among
many others [1–4].
Adipokines exhibit a wide range of functions including
the regulation of food intake and body weight homeostasis,
insulin sensitivity, reproduction, immunity, inflammation, or
vascular homeostasis [4, 5]. In obesity and type 2 diabetes
mellitus, there is an imbalanced adipokine production that
has been locally associated with AT inflammation, and the
onset of insulin resistance, but also with chronic systemic
inflammation, cardiovascular disease, and endothelial dys-
function [6]. In the context of metabolic diseases, adipokines
are not only key mediators in the complex crosstalk between
AT with other insulin-sensitive organs such as liver, skeletal
muscle, and AT itself, but also have an impact on the
cardiovascular system. Therefore, in the last years, there
is a growing interest in the potential role of adipokines
as biomarkers of low-grade inflammation and metabolic-
related cardiovascular complications. In this review, we will
specifically focus on the adipokine visfatin/Nampt and its
impact on the cardiovascular (CV) system.
2 Mediators of Inflammation
2. Visfatin/Nampt: An Adipokine and Beyond
In 2005, Fukuhara et al. firstly described visfatin as an
adipokine exhibiting insulin mimetic properties in mice
[2]. However, the expectation initially arisen by the novel
adipokine was soon blunted when the authors had to retract
their paper due to the lack of reproducibility of the hypo-
glycemic properties [5]. Visfatin was found identical to pre-B
cell colony-enhancing factor (PBEF), a previously described
cytokine promoting maturation on early B-lineage precursor
cells [6].
The term visfatin refers to visceral fat, since it was initially
suggested that visfatin was mainly produced in visceral fat
compared to subcutaneous fat in both mice and humans [2].
Nevertheless, other groups have later reported similar visfatin
levels in human subcutaneous and visceral fat tissue [7, 8].
Importantly, visfatin is also found in other fat depots such as
perivascular and epicardial fat [9, 10], where it might exert
a paracrine cardiovascular effect as will be further discussed.
Within the adipose tissue, visfatin is not only synthesized and
released by adipocytes but also by inflammatory cells, like
activated macrophages, whose infiltration in AT is markedly
increased in relation with obesity [11].
Visfatin displays intrinsic enzymatic activity as a nicoti-
namide phosphoribosyltransferase (Nampt), as reported in
2002 by Rongvaux et al. [12]. In mammals, intracellu-
lar Nampt catalyzes the rate-limiting step in the salvage
pathway leading to the synthesis of nicotinamide adenine
dinucleotide (NAD+), an essential coenzyme in multiple
cellular redox reactions [13, 14]. More specifically, Nampt
synthesizes nicotinamide mononucleotide (NMN) and inor-
ganic pyrophosphate by condensing nicotinamide and 5-
pyrophosphoribosyl-1-pyrophosphate (PRPP). In a second
step, NMN is transformed into NAD by nicotinamide
mononucleotide adenylyltransferase (Nmnat) [14].
In mammals, two isoforms of Nampt have been de-
scribed. Intracellular Nampt (iNampt), which plays a central
role in maintaining the activity of NAD-dependent enzymes,
is implicated in the regulation of cellular metabolism in
response to nutrient availability, maturation and cell survival
[14–17]. On the contrary, the other isoform, extracellular
Nampt (eNampt), is secreted by different cell types [18]. In
this review, we will mainly focus on eNampt as this isoform
may represent a mediator of interorgan crosstalk.
In the current literature, we find indistinctly the terms
visfatin/Nampt/PBEF to refer to this adipokine. According
to the HUGO Gene Nomenclature Committee (HGNC) and
the Mouse Genomic Nomenclature Committee (MGNC) the
official nomenclature of the gene and the protein is Nampt
[19]. However, since the Nampt activity is not always medi-
ating visfatin/Nampt effects, we will employ visfatin/Nampt
throughout this review.
In the last years, visfatin/Nampt has indeed arisen as a
multifaceted and ubiquitously expressed molecule that exerts
multiple biological actions beyond the adipose tissue [20,
21]. Indeed, among adipocytes, visfatin/Nampt is expressed
in a wide range of cell types from the immune system,
chondrocytes, and amniotic epithelium cells among others
[11, 22, 23]. In 1994, Samal et al. initially provided qualitative
evidence for visfatin expression in lysates from human heart,
pancreas, liver, and skeletal muscle at mRNA levels [6]. More
recently, visfatin protein expression has been reported in
human myoblasts [24] and human hepatocytes, from which
visfatin is actively secreted [25].Moreover, visfatin expression
in liver and skeletal muscle has been further confirmed by
other studies [26, 27], raising the possibility that these organs
could be potential sources of visfatin plasma levels and thus
contributing to metabolic interorgan crosstalk.
3. Circulating Visfatin/Nampt as a Biomarker
of Inflammation, and CV Disease
3.1. Obesity, Type 2 Diabetes and the Metabolic Syndrome.
Obesity and type 2 diabetes represent two independent risk
factors for inflammation-related atherothrombotic diseases.
In the context of metabolic diseases, most studies have
reported elevated circulating levels of visfatin/Nampt in
different clinical conditions, such as obesity, type 2 diabetes
mellitus, and the metabolic syndrome which represent inde-
pendent risk factors for inflammation-related atherothrom-
botic diseases [28, 29]. Nevertheless, as reviewed by others,
there are conflicting results in different reports studying the
variation of visfatin/Nampt levels in these disease states,
where circulating visfatin/Nampt levels have been found
unmodified or even lower compared to healthy controls
[29, 30]. However, in the last years, several studies have
established positive associations between enhanced circu-
lating visfatin/Nampt levels and atherogenic inflammatory
diseases, therefore supporting a role for visfatin as a potential
biomarker of cardiovascular complications associated to
metabolic disorders.
In the last years, visfatin/Nampt has been proposed as
a marker of endothelial dysfunction, an initial and crucial
step in the progression of the atherosclerotic process [31].
In type 2 diabetic patients, it has been reported a strong
correlation between visfatin/Nampt levels and impaired vas-
cular endothelial function determined as brachial artery
flow-mediated dilation (FMD) and creatinine clearance [32].
Although in this latter work, no association was found
between inflammatory markers, such as high-sensitivity
C-reactive protein (hsCRP) and fibrinogen, neither with
atherosclerosis, as evaluated by assessing intima-media thick-
ness (IMT), and so the authors concluded that visfatin/Nampt
is more likely not a surrogate marker of inflammation nor
atherosclerosis. Additionally, Uslu et al. have found that type
2 diabetic patients display enhanced circulating visfatin levels
which positively correlate with enhanced levels of the marker
of endothelial dysfunction homocystein. Surprisingly, this
work could not find a positive correlation between visfatin
levels in type 2 diabetic patients and asymmetric dimethy-
larginine (ADMA), the major endogenous inhibitor of the
endothelial nitric oxide synthase (eNOS) [33]. Homocysteine
has been proposed as an intermediate factor in the rela-
tionship between endothelial dysfunction and renal function
[34].
In both patients with the metabolic syndrome and type 2
diabetes, it has been suggested that enhanced visfatin/Nampt
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levels are associated with advanced carotid atherosclero-
sis, estimated as the intima-media thickness (IMT) in this
artery [35, 38]. Indeed, Kadoglou et al. have proposed
visfatin/Nampt circulating levels as a marker of advanced
carotid atherosclerosis for type 2 diabetic patients. In mor-
bid obese patients, epicardial fat thickness as assessed by
echocardiography was related to enhanced visfatin/Nampt
and plasminogen activator inhibitor-1 (PAI-1) levels as well
as visceral obesity [36].
On the contrary, some authors claim that high vis-
fatin/Nampt levels, instead of depicting changes in the
atherosclerotic process are more likely reflecting changes in
the systemic inflammation in patients with renal and cardio-
vascular disease. Thus, in patients undergoing hemodialysis,
visfatin/Nampt levels are associated with high-sensitivity
C-reactive protein (hsCRP), considered one of the most
powerful predictors of atherosclerosis and vascular death,
but not with other parameters of atherosclerosis such as
ADMA levels, aortic pulse wave, brachial pressure index in
the ankle, or the percentage of calcification in the abdominal
aortic wall [45]. In this line, Visfatin/Nampt expression is
upregulated in circulating blood monocytes from obese type
2 diabetic patients compared to nondiabetic obese patients
[50], indicating that enhanced visfatin/Nampt expression
may be related to type 2 diabetes rather than obesity. On
the contrary, Oki et al. [51] have reported that serum
visfatin/Nampt levels positively correlate with inflamma-
tory markers, independently of the insulin resistance state.
Hence, the significance of visfatin/Nampt levels variations in
metabolic diseases remains to be more accurately addressed.
However, it seems clear that visfatin/Nampt levels are posi-
tively associated to a series of inflammatory conditions, inde-
pendently of other potential metabolic implications. Thus,
serum visfatin/Nampt levels have been positively correlated
with circulating inflammatory markers, such as IL-6, CRP,
and MCP-1 [40, 45, 51].
3.2. Chronic Kidney Disease. Diabetes is the main risk factor
for the development and progression of chronic kidney
disease (CKD) [52, 53]. In patients with CKD, visfatin/Nampt
levels positively correlate with soluble markers of endothelial
dysfunction such as vascular, intercellular, and melanoma
cells adhesion molecule-1 (VCAM-1, ICAM-1, and MCAM-
1, resp.) [43, 44]. The relation between visfatin/Nampt levels
and endothelial function in CKD is not merely descriptive,
but may also have a functional impact, since visfatin/Nampt
levels negatively correlate with endothelial function esti-
mated as flow-mediated dilation (FMD) in brachial artery
or glomerular filtration rate (GFR) [41, 42]. Indeed, the
improvement of endothelial function after kidney trans-
plantation correlates with a reduction in circulating vis-
fatin/Nampt levels [46].
3.3. Polycystic Ovary Syndrome. Visfatin/Nampt has been
recently proposed as a candidate in the pathogenesis
of endothelial dysfunction in polycystic ovary syndrome
(PCOS), the main androgen excess disorder in women [39].
PCOS is characterized by obesity, insulin resistance, and
endothelial dysfunction. It has been previously proposed that
PCOS is associated with a dysfunctional secretion pattern of
adipokines. In this regard, enhanced visfatin/Nampt levels
and expression in AT have been previously reported in PCOS
[8, 54]. Interestingly, enhanced visfatin/Nampt levels have
been associated with reduced brachial artery flow-mediated
vasodilatation in patients with PCOS and significantly pre-
dicted impaired endothelial function [39]. Similar to what
described for type 2 diabetic patients by Takebayashi et al.
visfatin/Nampt levels did not correlate with inflammatory
markers as hsCRP or carotid IMT.
3.4. Preeclampsia. Preeclampsia is a hypertensive disorder in
pregnancy and is associated with increased cardiovascular
disease (CVD) risk later in life and is a major cause of
maternal and fetal mortality and morbidity in pregnancy
[55]. Preeclampsia shares cardiovascular risk factors with
the metabolic syndrome such as subclinical inflammation,
insulin resistance, and obesity. Since visfatin/Nampt levels
are enhanced in all these pathological conditions, several
groups have aimed to determine if visfatin/Nampt may
contribute to preeclampsia. Thus, different groups have
reported enhanced maternal visfatin/Nampt serum levels in
preeclamptic patients compared to their matched pregnant
controls [37, 56, 57]. Furthermore, Fasshauer et al. also
found positive correlations between visfatin/Nampt serum
concentrations and age, blood pressure, creatinine, free fatty
acids (FFA), and the inflammatory markers IL-6 and CRP
[37]. On the contrary, other groups suggest that decreased
expression of visfatin, as a proangiogenic factor, may be
associated with the pathogenesis of preeclampsia. Thus, Hu
et al. have reported that maternal plasma visfatin/Nampt
levels were downregulated in women with mild preeclampsia
and to a higher extent in women with severe preeclampsia
[58]. In this line, it has been recently reported by Kim
et al. that in placental biopsies visfatin/Nampt expression
is reduced compared to the visfatin/Nampt levels in pla-
centas from normotensive women [59]. Reduced placental
perfusion is an initial event in preeclampsia, initiating a
sequence of events leading to altered vascular function and
hypertension. Thus, decreased placental perfusion-induced
endothelial dysfunction has been suggested as the cause
leading to progressive vasoconstriction, hyperresponsive-
ness, and impaired relaxation of uterine arcuate arteries [60].
However, it has been recently demonstrated that impaired
placental perfusion is not the mechanism responsible for
visfatin/Nampt induction in preeclampsia [56]. Ognjanovic
et al. have demonstrated that visfatin/Nampt is also locally
expressed in foetal membranes and secreted from amniotic
epithelium cells in the human placenta and that its secretion
is increased in response to proinflammatory stimuli such as
lipopolysaccharide (LPS) and IL-1𝛽 [23]. On the other hand,
exogenous administration of visfatin/Nampt to human foetal
membranes leads to an increase in inflammatory cytokines
such as IL-1𝛽, TNF-𝛼, and IL-6 [23, 61]. Visfatin/Nampt
also prevented actinomycin D-induced apoptosis, therefore
suggesting a protective role for visfatin/Nampt in preventing
apoptosis induced by chronic distension, labor, or infection
in the placenta [61]. Thus, whether enhanced visfatin/Nampt
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levels is a deleterious factor promoting endothelial dysfunc-
tion in placenta and leading to preeclampsia or, if on the
contrary, is a beneficial factor preventing apoptosis under
inflammatory conditions and promoting angiogenesis in the
placenta, or if it is just a biomarker, is still an open question
[62].
3.5. Acute Coronary Syndromes. Enhanced circulating vis-
fatin/Nampt levels have been proposed to correlate with
the development of atherosclerotic plaques, and thus vis-
fatin/Nampt has been proposed as amarker of atherosclerosis
by several groups [35, 40]. It has been described that in
coronary artery diseases (CADs), and more specifically in
acute coronary syndrome, circulating inflammatory mark-
ers such as IL-6 and MCP-1 positively correlate with vis-
fatin/Nampt levels [40]. In patients with coronary artery
disease (CAD) and acute myocardial infarction, a positive
association between visfatin/Nampt expression and unsta-
ble atherosclerotic lesions has been established [63]. Inter-
estingly, another positive correlation has been established
between visfatin/Nampt expression in both pericardiac and
periaortic fat and coronary artery atherosclerosis [64], which
underpins that not only circulating but also perivascular
visfatin/Nampt may exert an important paracrine effect
promoting the development of atherosclerotic lesions. A
higher expression of visfatin/Nampt has been found not only
in the smooth muscle within atherosclerotic plaques [64]
but also in foam cells of unstable plaques from patients
that suffered an acute myocardial infarction [63]. There-
fore, it has been proposed that visfatin/Nampt localization
within the lesions may be related to atherosclerotic plaque
destabilization [63]. In this line, Yu et al. have recently
described that visfatin/Nampt levels are upregulated in the
circulation of patients suffering a ST-segment elevation
myocardial infarction (STEMI), the most acute form of MI.
Furthermore, the authors found enhanced visfatin/Nampt
expression in macrophages present in the coronary rupture
plaques.These results support the hypothesis that leukocytes-
derived visfatin/Nampt may play a role in the pathogenesis
of coronary plaques rupture. Importantly, this group has pre-
viously proposed that enhanced circulating visfatin/Nampt
levels associate with the occlusion of infarct-related artery
(IRA) and circulating hsCRP levels [48] and associate with
the degree of myocardial damage [49]. In the light of the
bulk of evidence presented herein, visfatin/Nampt arises as
a relevant molecule promoting plaque destabilization and
rupture in different types of acute coronary syndromes.
3.6. Cerebrovascular Diseases. Visfatin/Nampt has also been
proposed to play a role in cerebrovascular diseases [65].Thus,
Lu et al. have demonstrated that plasma visfatin/Nampt was
increased in a Chinese population of patients with ischemic
stroke and correlatedwith hsCRP levels in these patients [47].
In this line, it has been recently proposed that aging decreases
intracellular visfatin/Nampt expression in the murine brain,
in parallel to increased visfatin/Nampt circulating plasma
levels, and may contribute to endothelial dysfunction in the
brain [66].
3.7. Non-metabolic Chronic Inflammatory Diseases. In the
context of other non-metabolic chronic inflammatory dis-
eases characterized by systemic inflammation enhanced vis-
fatin/Nampt levels have been additionally reported. Thus,
visfatin/Nampt circulating levels are enhanced in osteoarthri-
tis [67, 68], Crohn’s disease, and ulcerative colitis [20, 69].
Moreover, in patients with acute lung injury (ALI), vis-
fatin/Nampt is currently considered a biomarker of this dis-
ease [70]. Visfatin/Nampt also seems to play a role in several
types of infections like sepsis [71] or intrauterine infection
(chorioamnionitis) [61, 72]. Additionally, visfatin/Nampt also
mayhave a crucial role in autoimmune inflammatory diseases
since enhanced visfatin/Nampt levels have been reported in
psoriasis [53], rheumatoid arthritis (RA) [43], and inflam-
matory bowel disease (IBD). Interestingly, visfatin/Nampt
has been identified as a novel “universal marker of chronic
inflammation” whose RNA is upregulated in the mononu-
clear cells from peripheral blood from patients suffering any
of these three chronic inflammatory diseases, which allows to
discriminate patients with chronic inflammation and healthy
controls mRNA expression levels [73].
In RA, it has been proposed that visfatin/Nampt can be a
potent mediator of inflammation [67]. However, Senolt et al.
provided evidence for a positive correlation between the
levels of serum visfatin/Nampt and total number of B cells
in RA, more than activity of the disease [74]. Indeed both
visfatin/Nampt levels and B cell number were reduced after
treatment with rituximab.
In patients with psoriasis, it has been speculated that
visfatin enhanced levels may lead to atherosclerosis and
vascular complications as frequent comorbidities found in
this disease [75]. Analogously, it has been suggested that the
proinflammatory and matrix-degrading activities of visfatin
reported in the context of RA [67] may contribute to the
enhanced risk for CVD in these patients [76]. However, the
relation between enhanced visfatin levels and CVD in these
inflammatory diseases needs to be further explored.
In the light of all these studies, we can conclude that
visfatin/Nampt is upregulated and may play a role in both
atherosclerosis and endothelial dysfunction (Table 1). But
beyond being a marker for CVD, growing evidence supports
a role for visfatin/Nampt as direct factor triggering vascular
injury. Here, we will try to summarize the most relevant
previous and recent evidences about visfatin/Nampt direct
actions on the cardiovascular system (Figure 1). More specif-
ically, we will focus on visfatin/Nampt effect on proliferation,
and angiogenesis of vascular cells, visfatin/Nampt inflam-
matory effects, extracellular matrix degradation and finally
apoptosis/cell survival.
4. Direct Cardiovascular Actions of
Visfatin/Nampt
4.1. Cell Proliferation and Angiogenesis. Proliferation of vas-
cular smooth muscle cell (VSMC) is a hallmark of the
development of atherosclerotic lesions. Importantly, perivas-
cular visfatin/Nampt can act as a growth factor in vascular
smoothmuscle cells, promoting cell proliferation in rat aortic
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∙ Release of TNF𝛼 and IL-8
Figure 1: Diagram summarizing the main reported direct actions of visfatin/Nampt in cells in the cardiovascular system, namely, cardiac
fibroblast and cardiomyocytes, mesangial cells, monocytes and macrophages, smooth muscle cells, and endothelial cells. eNOS: endothelial
nitric oxide synthase, IL-8: interleukin-8, MMP-2/9: matrix metalloproteinase-2/9, NO: nitric oxide, RAS: renin-angiotensin system, and
TNF-𝛼: tumor necrosis factor-𝛼.
Table 1: Summary of the main correlations reported between visfatin circulating levels and CV disease in human subjects.
Clinical condition Main correlations found References
↔TD2 +Endothelial dysfunction (FMD) [32]
↑TD2 +Homocystein, ±ADMA [33]
↑TD2 +Carotid IMT [35]
↑Morbid obesity +Epicardial fat thickness, +PAI-1 [36]
↑Preeclampsia +CRP, +IL-6, +blood pressure, and +free fatty acids [37]
↑Metabolic syndrome +IL-6, +MCP-1, and +IMT [38]
↑Metabolic syndrome +Blood pressure [29]
↑PCOS +Endothelial dysfunction (FMD), ±hsCRP, and ±IMT [39]
↑CAD +MCP-1, +IL-6 [40]
↑CKD −GFR, +TD2, and +endothelial dysfunction (FMD) [41]
↑CKD +GFR, +IL-6, +CRP, and +sVCAM-1 [42]
↑CKD +sVCAM-1, +sICAM-1, and +MCAM [43, 44]
↑Hemodialysis ±Atherosclerosis, +hsCRP [45]
↑Renal transplantation +Endothelial function (FMD) [46]
↑Ischemic stroke +hsCRP, −LDLc [47]
↑STEMI +Occlusion IRA, +hsCRP, and +myocardial damage [48, 49]
↔: no change in circulating visfatin levels. ↑: enhanced circulating visfatin levels. ↓: reduced circulating visfatin levels. +: positive correlation reported, −:
negative correlation reported, ±: no significant correlation reported. CAD: coronary artery disease, FMD: flow-mediated dilation, GFR: glomerular filtration
rate, hsCRP: high-sensitivity C-reactive protein, IL: interleukin, IMT: intima-media thickness, IRA: infarct-related artery, LDLc: low-density lipoprotein-
associated cholesterol, MCAM: melanoma cell adhesion molecule, MCP-1: monocyte chemotactic protein-1, PAI-1: plasminogen activator inhibitor-1, PCOS:
polycystic ovary syndrome, sICAM: soluble intercellular adhesionmolecule, sVCAM: soluble vascular cell adhesionmolecule, andTD2: type 2 diabetesmellitus.
smooth muscle cells though Nampt enzymatic activity [10].
Visfatin/Nampt emerges as a player in the development and
progression of atherosclerotic lesions by directly promoting
smooth muscle cell proliferation.
Aberrant angiogenesis is now considered a feature of
the atherogenic process in both coronary and carotid dis-
eases [77]. In this line, it has also been described that
visfatin/Nampt can promote endothelial cell proliferation,
migration, and capillary tube formation in a concentration-
dependent manner in HUVEC [78–81]. These proliferative
effects of visfatin/Nampt seem to be mediated, or at least
partially mediated, by a master molecule in endothelial pro-
liferation and neovessel formation: vascular endothelial cell
growth factor (VEGF) [78].Thus, visfatin/Nampt upregulates
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VEGF synthesis and secretion as well as the expression of
the VEGF receptor 2, which has been proposed to mediate
the angiogenic actions of VEGF [78, 82]. Besides VEGF,
visfatin/Nampt upregulates the production of other pro-
angiogenic soluble factors, such as fibroblast growth factor-
2 (FGF-2), MCP-1, and IL-6, in endothelial cells [82–84].
Indeed, both MCP-1 and FGF-2 have also been identified
as mediators of visfatin/Nampt-induced angiogenesis [82,
83]. Beyond in vitro studies, the angiogenic activities of
visfatin/Nampt have been demonstrated in ex vivo and
in vivo approaches [78, 79]. Thus, visfatin/Nampt is able
to induce the formation of functional neovessels in chick
chorioallantoic membrane and mouse Matrigel plug [79]. In
this line, it has been described that the injection delivery of a
plasmid containing visfatin/Nampt improved limb perfusion
in a mouse undergoing unilateral hindlimb ischemia [80].
Furthermore, visfatin/Nampt enhances the expression,
protein levels and activity of matrix metalloproteinases,
MMP-2/9, which are enzymes promoting angiogenesis
through the degradation of the extracellular matrix, while
it decreases the levels of their tissue inhibitors, TIMP-1
and -2, respectively [78]. The impact of visfatin on matrix
remodelling will be discussed in more detail below.
The forementioned proangiogenic properties of vis-
fatin/Nampt make of this adipokine a potential therapeutic
candidate in diseases where neovascularisation is necessary
to overcome restricted blood flow supply such as ischemic
stroke or macrovascular peripheral limb ischemia. Very
recently, Kim et al. have proposed that visfatin/Nampt
proangiogenic effects are mediated by the induction of
thromboxane synthase (TSA) with the subsequent TXA
2
release by endothelial cells (HMECs and HUVECs) [85]. The
authors more specifically demonstrate that visfatin/Nampt
upregulation of IL-8 via TXA
2
is the responsible mechanism
for visfatin/Nampt-induced angiogenesis [85].
It has been recently proposed that visfatin/Nampt exerts a
neuroprotective role for photothrombosis-induced ischemia
with both in vitro and in vivo approaches/models [86].
Thus, heterozygous visfatin/Nampt knockout mice (Pbef+/−)
display larger size of ischemic lesions than wild-type mice
[86]. On the other hand, visfatin/Nampt may contribute to
exacerbated angiogenesis leading to ischemic heart disease,
diabetes, or atherosclerosis andmay therefore arise as a novel
pharmacological target for treating such conditions.
Visfatin/Nampt proangiogenic actions also promote
tumor growth. Thus, circulating visfatin/Nampt levels are
enhanced in several malignancies such as endometrial [87],
gastric, or colorectal cancers [88, 89]. Inhibition of NAD
enzymatic activity is an emerging therapeutic strategy for
cancer treatment [25, 90]. In this context, two Nampt
inhibitors, APO866 (or FK866) and CSH-828, are being used
in clinical trials as NAD-depleting anticancer agents [91, 92].
Visfatin/Nampt proliferative effects are not restricted to
the vascular wall, since visfatin/Nampt also promotes prolif-
eration in rat cardiac fibroblasts. The proliferation of cardiac
fibroblasts together with an excessive accumulation of extra-
cellular matrix represents the basis of myocardial fibrosis.
In vitro stimulation of cardiac fibroblasts by visfatin/Nampt
requires the activation of Akt/PKB and the MAPKs p38 and
JNK, but not ERK 1/2 [93]. Pillai et al. have described that
cardiac-specific overexpressing Nampt transgenic mice show
increased cardiac fibrosis. Moreover, both recombinant and
adenoviral Nampt delivery increased proliferation in vitro in
rat cardiomyocytes, which was inhibited by Nampt-blocking
antibody [94]. Taking into account that visfatin/Nampt is
expressed in periadventitial and apical epicardial adipose
tissues [64], and with the recent evidence that it is also
secreted by rat cardiomyocytes [94], not only circulating
visfatin/Nampt but also visfatin/Nampt locally produced in
the CV system could play a detrimental role in promoting
myocardial fibrosis and remodeling.
4.2. Inflammation. Growing scientific evidence supports that
visfatin/Nampt can directly promote vascular inflammation
by activating different cell types including endothelial cells
and vascular smooth muscle cells. Moreover, visfatin/Nampt
can also contribute to vascular inflammation through its
immunomodulatory properties on immune cells [69]. Thus,
visfatin/Nampt can exert direct actions onmonocytes.Hence,
visfatin/Nampt promotes the synthesis and release of pro-
inflammatory cytokines, such as tumor necrosis factor-
(TNF-) 𝛼 and IL-8, by peripheral mononuclear cells [63].
Additionally, visfatin/Nampt promotes macrophage survival
[95], which may help perpetuating vascular inflammation.
In cultured human vascular smooth muscle cells, our
group demonstrated for the first time that visfatin/Nampt
could directly exert inflammatory effects. Thus, exogenous
administration of visfatin/Nampt activates ERK 1/2 and NF-
𝜅B, resulting in enhanced expression of the inducible nitric
oxide synthase (iNOS) [96]. iNOS is a pro-inflammatory
enzyme contributing to dysregulated NO production and
subsequent peroxynitrite formation. Thus, iNOS induction
plays a key role in endothelial dysfunction and vascular injury
in diabetes-related vascular complications [104].
Several reports suggest that visfatin/Nampt can addi-
tionally promote endothelial activation. In HUVEC, vis-
fatin/Nampt activates the inflammation-related transcription
factor NF-𝜅B [82, 84, 97] and promotes the expression of
cell adhesion molecules, such as ICAM-1, VCAM-1, or E-
selectin [84, 97], as key molecules implicated in leuko-
cyte recruitment and early proatherosclerotic events [105].
Visfatin/Nampt further upregulates the release of several
cytokines and chemokines by endothelial cells, including IL-
6, IL-8, or MCP-1 and its putative receptor CCR2 [84, 98],
and thus promotes the adhesion of human THP-1 monocytes
to endothelial cells [98]. The MAPK ERK 1/2 and p38, as
well as PI3K and the intracellular generation of reactive
oxygen species, have been proposed as responsible molecules
in endothelial cell inflammation induced by visfatin/Nampt
[97, 98].
Nicotinamide adenine dinucleotide phosphate (NADPH)
oxidase is a superoxide anion-generating and proinflamma-
tory enzyme closely associated to endothelial dysfunction
[106]. Boini et al. have proposed that visfatin/Nampt induces
the activation of NADPH oxidase, increasing superoxide
anion production resulting in the disruption of microtubular
networks in GECs and increased glomerular permeability
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Table 2: Direct vascular proinflammatory actions of visfatin and their proposed underlying mechanisms.
Target cell type Cellular actions Mechanism of action References
Smooth muscle cells ERK 1/2-NF-𝜅B activationiNOS induction
Nampt activity,
insulin receptor independent [96]
Endothelial cells
NF-𝜅B activation Insulin receptor independent [82, 84, 97]
IL-6, IL-8 release N.D. [84, 98]
MCP-1 release N.D. [82, 98]
CCR2 expression N.D. [82]
ICAM-1, VCAM-1, and E-selectin Insulin receptor independent [84, 97]
induction
MMP-2 and MMP-9 activation N.D. [99]
NADPH oxidase activation Nampt activity (HUVEC) [100]
Lipid rafts (BCAEC and GEC) [101, 102]
Monocytes Binding to endothelial cells N.D. [84]
MMP-9 activation Insulin receptor independent [63]
Macrophages Cell survival
STAT3/IL-6 release Nampt- and
insulin receptor-independent [95]
Lipid accumulation SR-A, CD36 activation [103]
Peripheral blood mononuclear cells Cytokine release (IL-8, TNF-𝛼) Insulin receptor [63]
N.D.: not determined. BCAEC: bovine coronary artery endothelial cells, CCR2: chemokine receptor type 2, CD36: cluster of differentiation 36, ERK 1/2:
extracellular signal-regulated kinase 1/2, GEC: glomerular endotelial cells, HUVEC: human umbilical vein endothelial cells, ICAM-1: intercellular adhesion
molecule-1, IL: interleukin, MCP-1: monocyte chemotactic protein-1, MMP: matrix metalloproteinase, NF-𝜅B: nuclear factor-𝜅B, iNOS: inducible nitric oxide
synthase, SR-A: scavenger receptor-A, STAT3: signal transducer and activator of transcription 3, TNF-𝛼: tumor necrosis factor-𝛼, and VCAM-1: vascular cell
adhesion molecule-1.
[101]. Analogously, visfatin/Nampt triggers NADPH oxi-
dase subunits assembly and activation through lipid rafts
in bovine coronary artery endothelial cells [107], thereby
contributing to endothelial dysfunction in coronary cir-
culation. Alternative to NADPH activation, it has been
suggested that visfatin/Nampt deleterious effect on dia-
betic nephropathy may be due in part to the activation
of intrarenal renin-angiotensin system [108]. Inappropriate
activation of the renin-angiotensin system is known to be
implicated in CV diseases related to CKD. Thus, it has been
reported that visfatin/Nampt leads to activation of the renin-
angiotensin system by upregulating the expression levels of
renin, angiotensinogen and angiotensin I and II in a dose-
dependent manner in cultured rat mesangial cells [108].
In another clinical condition such as myocardial infarc-
tion, and more specifically in STEMI, visfatin/Nampt cir-
culating levels and intracellular expression in macrophages
and monocytes are enhanced [109]. Thus, Chiu et al. con-
clude that male patients with STEMI show increased vis-
fatin/Nampt expression in leukocytes, which may aggravate
the development of instability of atherosclerotic plaques
[109]. Interestingly, Zhou et al. have recently reported that
visfatin/Nampt promotes lipid accumulation mainly through
excessive cholesterol uptake in RAW264.7 macrophages and
in peritoneal macrophages isolated from ApoE knockout
mice and accelerates the process of atherosclerosis mainly
through modulating the expression of the macrophage scav-
enger receptor class A (SR-A) and CD36 [103] (Table 2).
4.3. Extracellular Matrix. Adya et al. reported that on one
hand visfatin/Nampt upregulated the expression and activity
of the matrix metalloproteinases (MMP)-2/9 and downreg-
ulated the expression of the inhibitors of these MMPs such
as TIMP-1 and -2, in monocytes and endothelial cells [78].
MMP-2 and -9 are pivotal enzymes in the degradation of
extracellular matrix (ECM), thus facilitating atherosclerotic
plaque vulnerability [110].
Cardiac fibrosis is the consequence of excessive accu-
mulation of ECM. As we have previously mentioned, vis-
fatin/Nampt may also contribute to cardiac fibrosis. Thus,
visfatin/Nampt not only promotes proliferation in rat cardiac
fibroblasts but also upregulates the mRNA expression and
protein levels of procollagen I and II in this cell type, leading
to enhanced types I and III collagen release [93].
Visfatin/Nampt has also been proposed to promote renal
fibrosis, a typical feature of CKD. In the context of CKD,
visfatin/Nampt promoted fibrosis in rat mesangial cells by
upregulating the synthesis of key profibrotic molecules such
as transforming growth factor-𝛽1 (TGF-𝛽1), PAI-1 and type I
collagen, thus increasing the risk for CVD [111]. These results
provide evidence for visfatin/Nampt as a novel factor promot-
ing cardiac and renal fibrosis whether directly upregulating
procollagen andMMPs secretion or indirectly contributing to
fibrosis by upregulating the secretion of other classic fibrosis
mediators such as TGF-𝛽 or PAI-1.
4.4. Cell Survival/Apoptosis. There are conflicting results
regarding the role of visfatin/Nampt in the regulation of
cell survival and apoptosis. On one hand, intracellular vis-
fatin/Nampt plays a central role in maintaining the activity
of NAD-dependent enzymes regulating cellular metabolism
[14–17]. On the other hand, extracellular visfatin/Nampt
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exerts antiapoptotic effects and promotes cell survival in sev-
eral cardiovascular cells. Thus, it has been demonstrated that
visfatin/Nampt attenuates cell apoptosis induced by hydrogen
peroxide in human endothelial cells [99], rat VSMC [10], and
in both rat cardiac fibroblasts [93] and cardiomyocytes [94].
Several works have suggested that visfatin/Nampt could
exert direct cardioprotective effects. In cultured murine
cardiomyocytes undergoing hypoxia and reoxygenation, vis-
fatin/Nampt administered at the time of reoxygenation,
triggered delayed cell death, due at least in part to a delayed
opening of the mitochondrial permeability transition pore
(mPTP) by oxidative stress. The mPTP is a nonspecific
mitochondrial channel, whose opening in the first minutes
of reperfusion is a critical determinant of cardiomyocyte
death [112]. Cardiac specific Nampt overexpression in mice
has been proposed to prevent myocardial injury in response
to myocardial ischemia and reperfusion [113]. Intravenous
administration of visfatin/Nampt at the time of reperfusion
reduced the infarct size in a mouse model of ischemia-
reperfusion [114]. On the contrary, Pillai et al. have reported
that both exogenous visfatin/Nampt and visfatin/Nampt
overexpressions promote cardiac hypertrophy and adverse
ventricular remodeling [94].
On the other hand, intracellular Nampt activity is
acknowledged to play a central role in cell maturation and
survival in smooth muscle cells in vitro [16, 17]. Van der
Veer et al. have demonstrated that iNampt is crucial in order
to induce maturation and prevent premature senescence in
human VSMC [16, 17].
Zhang et al. have reported that visfatin/Nampt knockout
heterozygousmice (Pbef+/−) subjected to photothrombosis, a
cerebral ischemiamodel, displayedmore severe brain damage
and neuronal degeneration compared to wild-typemice [86].
In a model for cerebral ischemia in rats, Nampt overex-
pression in brain prevented neuronal death [115]. Therefore,
visfatin/Namptmay represent an interesting pharmacological
tool to treat both cardiac and cerebral damage derived from
ischemia-reperfusion.
Importantly, visfatin/Nampt promotes macrophage sur-
vival through a mechanism involving the release of IL-6 [95].
Moreover, visfatin/Nampt also inhibits neutrophile apoptosis
in clinical and experimental sepsis [71].Thus, visfatin/Nampt
can help to perpetuating cell-mediated inflammation at the
sites of elevated concentrations of this adipocytokine.
4.5. Vascular Tone. Impairment of endothelial vasodilatory
responses is one of the earliest markers of vascular disease
[116]. To date, there are only scarce and conflicting reports
analyzing the direct actions of visfatin/Nampt vascular tone
regulation.
In human umbilical vein and coronary artery endothelial
cells (HUVEC; HCAEC), extracellular visfatin/Nampt can
enhance endothelial nitric oxide synthase (eNOS) expression
and activity resulting in enhanced NO production [80]. This
in vitro study does not support a role for visfatin/Nampt as
a biomarker of endothelial dysfunction in clinical conditions
such as CKD or type 2 diabetes as previously summarized.
Hence, this effect on eNOS and NO production was not
considered beneficial by the authors, who associated them to
endothelial cell proliferation and angiogenesis considered as
two deleterious proatherosclerotic events [80]. Analogously,
it has been reported that visfatin, addition to an organ bath
triggers the relaxation of noradrenaline (NA) precontracted
rat aortic rings [117].
On the contrary, Xia et al. have shown that visfatin/Nampt
inhibits the vasorelaxant response to BK in bovine coronary
arteries through NADPH oxidase activation by membrane
raft clustering [102]. In this line, our group has provided
the first evidence for visfatin/Nampt as an active player
in endothelial dysfunction in humans. Thus, we propose
that besides a novel biomarker in this clinical condition,
visfatin/Nampt is an active agent promoting endothelial dys-
function.We have demonstrated that visfatin/Nampt impairs
endothelium-dependent relaxations in both rat and human
mesenteric microvessels [100]. Importantly, the impair-
ment of endothelium-dependent relaxation exerted by vis-
fatin/Namptwasmediated byNADPHoxidase activation and
required Nampt enzymatic activity. Visfatin/Nampt directly
enhancedNADPHoxidase activity as determined inHUVEC
and rat microvessels. On the contrary, both the Nampt
inhibitors, APO866 or the NADPH inhibitor apocynin, pre-
vented visfatin/Nampt-induced impaired endothelial vasore-
laxation [100]. In opposition to the relaxation exerted by
visfatin/Nampt in noradrenaline precontracted aortic rings
described byYamawaki et al. we did not observe any influence
of visfatin/Nampt on NA-induced vasoconstriction in rat
mesenteric microvessels [117]. Our results are in line with
the activation of NADPH oxidase by visfatin/Nampt in
bovine coronary artery endothelial cells reported by Xia et
al.Therefore, more in-depth studies using both in vivo and in
vitro approaches are needed to fully understand the capacity
of visfatin/Nampt to impair vasodilation.
5. Mechanisms of Action of Visfatin/Nampt in
the CV System
5.1. The Insulin Receptor. Visfatin/Nampt was initially pro-
posed by Fukuhara et al. as a potential beneficial tool
able to bind and activate the insulin receptor triggering
glucose-lowering properties [2]. However, two years later,
the authors retracted their paper, and the role of insulin
receptor in visfatin/Nampt-mediated actions is still a matter
of controversy [5]. In this line, the glucose-lowering actions of
visfatin/Nampt have been hardly reproduced.However, in the
context of CV diseases it has been proposed that the insulin
receptor mediates some of the in vitro effects reported for
visfatin/Nampt on IL-8 and TNF-𝛼 secretion of by human
peripheral blood mononuclear cells [63], the upregulation
of MMP-9 in THP-1 monocytes [63], or enhanced glucose
uptake by rat mesangial cells [118]. On the contrary, a role for
insulin receptor has been discarded in a wide range of cell
types, including vascular cells and macrophages [10, 95, 97].
5.2. Nampt Activity. Nampt enzymatic activity has been pro-
posed as an alternativemechanism for visfatin/Nampt actions
in the CV system. Thus, the pharmacological inhibition of
iNampt by APO866 decreased cell survival and promoted
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senescence in VSMC [17]. On the contrary, eNampt activity
has been proposed to exert proatherogenic effects in smooth
muscle cells. Wang et al. have reported that visfatin/Nampt
from PVAT can promote smooth muscle cells proliferation
through an eNampt-dependent mechanism [10].
Moreover, blockade of the insulin receptor did not
affect the reported inflammatory effect of visfatin/Nampt in
smooth muscle cells while APO866, the inhibitor of Nampt,
completely prevented visfatin/Nampt-induced inflammatory
signaling [96]. Additionally, we demonstrated that vis-
fatin/Nampt impaired endothelium-dependent relaxation in
rat and human mesenteric microvessels through its intrinsic
eNampt activity [100]. Thus, in the presence of the Nampt
inhibitor APO866, visfatin/Nampt deleterious effects on the
endotheliumwere prevented.This proinflammatory profile of
eNampt activity is further supported by the observation that
inflammatory cytokine secretion by leukocytes is regulated by
eNampt activity [119].
On the other hand, it has been proposed that eNampt
may enhance intracellular NAD+ levels conferring a higher
resistance of cardiomyocytes to oxidative stress in ischemia-
reperfusion [113]. On the contrary, a deleterious role has also
been proposed for eNampt activity in myocardial infarction.
Thus, Montecucco et al. have very recently shown that
treatment with of the Nampt inhibitor APO866 reduced
myocardial infarct size, neutrophil infiltration, and reactive
oxygen species (ROS) generation within infarcted hearts in
vivo in a mouse model of ischemia and reperfusion [120].
Moreover, exogenous administration of APO866 prevented
CXCL2-induced neutrophil recruitment and thereby reduced
neutrophil-mediated tissue injury in mice in vitro [120].
Thus, the pharmacological inhibition of Nampt emerges
as an effective therapeutic tool to reduce smooth muscle
cell proliferation, inflammation, endothelial dysfunction,
and oxidative stress-mediated tissue damage in myocardial
infarction.
In this line, some of the vascular and renal actions of
visfatin/Nampt have also been attributed to the product of
Nampt activity, NMN [10, 96, 100, 115]. NMN, the product
of Nampt, exerted growth-factor-like activity in rat smooth
muscle cells, through the activation of MAPKs ERK 1/2 and
p38 [10]. Analogously, our group demonstrated that NMN,
the product of Nampt is able to reproduce the activation
of the ERK 1/2-NF-𝜅B signaling pathway induced by vis-
fatin/Nampt, leading to iNOS upregulation in human VSMC
[96]. Moreover, NMN was able to both impair endothelium-
dependent relaxation in rat and human microvessels. Anal-
ogously, NMN upregulated NADPH oxidase activity in rat
microvessels and HUVEC mimicking the effects exerted by
visfatin/Nampt. However, NMN does not always reproduce
visfatin/Nampt actions [95], indicating that visfatin/Nampt
may have other additional mechanisms of action.
Interestingly, it has been recently proposed that vis-
fatin/Nampt can induce prostaglandin E(2) (PGE(2)) syn-
thesis in chondrocytes by both Nampt activity and insulin
receptor activation [121]. Whether this dual mechanism of
action can be extrapolated to some of the detrimental effects
of visfatin/Nampt in the CV system needs to be further
explored.
5.3. Other Mechanisms. As stated before, PBEF was first
identified as an immunomodulatory cytokine able to syner-
gize with interleukin 7 (IL-7) and stem cell factor (SCF) to
promote pre-B cell colony formation [6]. A role for insulin
receptor in visfatin/Nampt-mediated cytokine release has
been discarded [69]. Analogously, the upregulation of the
CAMs induced by visfatin/Nampt human endothelial cells
did not depend on insulin receptor activation [84, 97]. In
this regard, Li et al. reported that visfatin/Nampt-induced
survival of macrophages under endoplasmic reticulum stress
was not mediated by Nampt activity nor through the insulin
receptor [95]. Therefore, Li and other authors have proposed
that the effects of visfatin/Nampt onmonocytes and endothe-
lial cells activation may be mediated by a yet unidentified
receptor. Interestingly, Xia et al. have proposed that vis-
fatin/Nampt may act as a ligand of inflammatory or death
receptor [102].Thus, they propose that visfatin/Nampt effects
on the impairment of endothelium-dependent vasodilation
in bovine coronary arteries may be mediated through a
death receptor, which leads to the formation of the signalling
platforms called membrane rafts (MRs) [102].This opinion is
supported by the observation that visfatin/Nampt enhanced
acid sphingomyelinase (ASMase) activity. ASMase is an
enzyme that promotes the clustering of membrane rafts
(MR) resulting in MR-associated transmembrane signaling.
This ASMase is translocated onto the plasma membrane via
membrane proximal lysosome trafficking and fusion upon
stimulation of death receptors [122]. Visfatin/Nampt phar-
macological or genetic silencing prevented MR clustering
and consequent formation of the MR signalling platforms
or signalosomes in coronary arterial ECs. Both the phar-
macological inhibition of ASMase with amitriptyline and
genetic silencing with siRNA almost completely abolished
visfatin/Nampt effects on endothelial injury. Moreover, the
authors claim that the death receptor agonist FasL mim-
icked the effect exerted by visfatin/Nampt on endothelium-
dependent vasodilation [102]. However, this hypothesis does
not match with the proposed antiapoptotic effects of vis-
fatin/Nampt in cardiomyocytes. Furthermore, it has been
recently reported that visfatin/Nampt has a protective effect
on oxygen peroxide-induced myocardial apoptosis, not by
inhibiting the death receptor-dependent apoptotic pathways,
but most likely acting on p53-mediated, mitochondria-
dependent apoptotic signaling and via involvement of the
AMPK signaling pathway in H9c2 cardiomyocytes [123].
6. Sources of Visfatin/Nampt with
Potential CV Impact
Visceral adipose tissue was initially proposed as the main
source of circulating visfatin/Nampt in humans [2]. Vis-
fatin/Nampt plasma levels were proposed to correlate with
the amount of visceral fat in humans as determined by com-
puterized tomography [2]. Nevertheless, further evidence has
demonstrated that visfatin/Nampt is expressed in similar
levels in human subcutaneous AT [7, 8]. As previously men-
tioned, visfatin/Nampt is found in perivascular and epicardial
fat and can therefore act in a paracrine manner on the CV
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system [9, 10]. Indeed, epicardial AT explants virtually release
the same levels as upper abdominal SAT [9]. Epicardial fat
(EF) is now considered a true kind of visceral adipose tissue
(VAT) depot surrounding the heart. The impact of epicardial
fat remains relatively unstudied and is now under intensive
investigation in order to explore its contribution to CVD due
to its ability to synthesize and release several inflammatory
adipokines. Indeed, epicardial fat has been proposed as a
marker of visceral adiposity [124] and as an indicator of
cardiovascular risk [125].
Aswe have previouslymentioned,macrophages represent
a major source of visfatin/Nampt in AT [11]. In line with
the proposed inflammatory properties of visfatin/Nampt,
other circulating cytokine-producing cell types have been
described as sources of visfatin/Nampt, namely, activated
lymphocytes, monocytes, or neutrophiles [6, 63, 71].
Therefore, it is not striking that visfatin/Nampt expression
has been reported in macrophages from atherosclerotic
plaques [35, 63, 109]. However, besides being expressed in
macrophages and foam cells, visfatin/Nampt is also found in
different cell types present in the vascular wall. Thus, visfatin
expression has been reported in both coronary and aortic
VSMCs [64]. A single report by Lovren et al. has proposed
the human endothelial cells (HUVECs and HCAECs) as an
additional source for visfatin/Nampt within the vascular wall
[80]. In this line, visfatinmRNAexpression has been reported
in endothelial cells [126].
These observations suggest that, besides cells of circulat-
ing origin, other cell types from the atherosclerotic lesion can
represent an additional source of this adipocytokine, which
may then reach high local concentrations within the vascular
wall.
Cardiomyocytes have very recently been discovered
as a visfatin/Nampt-secreting cell type [94]. Indeed, vis-
fatin/Nampt secretion by cardiomyocytes is enhanced in
response to stress and has been proposed to induce cardiac
hypertrophy and fibrosis through the activation of JNK1,
p38, and ERK. These results suggest that visfatin/Nampt
is a positive regulator of cardiac hypertrophy and adverse
ventricular remodeling [94]. Therefore, although VAT may
be the main source contributing to circulating levels of vis-
fatin/Nampt, we cannot ignore the impact of visfatin/Nampt
from other adipose depots such as PVAT or EF that can
act in a paracrine manner in the CV system. Moreover,
visfatin/Nampt from activated immune cells, prone to be
recruited into the vascular wall, or locally synthesized vis-
fatin/Nampt by cardiomyocytes or vascular cells may also
contribute in an autocrine manner to the reported impact of
visfatin/Nampt in the CV system.
7. Conclusions
In 2005, visfatin/Nampt was identified as a novel adipocy-
tokine with suggested beneficial effects in the context of
metabolic disorders, as an insulin-mimetic with glucose-
lowering properties. The retraction of Fukuhara and col-
leagues combined with growing evidence supporting a role
for visfatin/Nampt in metabolic diseases suddenly shifted
the role of this adipokine from friend to foe. However, in
light of the recent advances in the field, to the question “vis-
fatin/Nampt: friend or foe?”, the answer should be “depending
on the scenario.”
As discussed in this review, there is growing clinical
evidence supporting a role for visfatin as a biomarker or even
a predictor of inflammation, and endothelial injury in several
metabolic diseases.
Importantly, in vitro and ex vivo approaches have now
provided evidence that visfatin/Nampt may exert direct
deleterious actions on the cardiovascular system, includ-
ing cell proliferation, monocyte/macrophage activation and
recruitment, vascular inflammation and remodeling, all of
which leading to the development of atherosclerotic lesions.
In this context, the pharmacological inhibition of the car-
diovascular actions of visfatin might represent a novel
therapeutic approach to prevent and treat cardiometabolic
complications. In the same line, the inhibition of visfatin
proangiogenic actions might also be useful in treating but
pathologies implying excessive neovascularization. Indeed,
there are currently ongoing clinical trials at an early phase in
this direction. In this context, the pharmacological inhibition
of the cardiovascular actions on the visfatin/Nampt might
represent a novel therapeutic approach to prevent and treat
cardiometabolic complications.
On the other hand, beneficial actions have also been
proposed for visfatin/Nampt, since the administration of
visfatin/Nampt has shown beneficial effects in ischemia-
related clinical conditions, such as stroke, peripheral limb
ischemia, or myocardial ischemia-reperfusion, where it may
become a beneficial pharmacological tool.
Although visfatin has emerged in the last years as a
promising pharmacological target in the context of cardio-
vascular complications, further research is still required to
understand the impact of visfatin in different scenarios and
clinical conditions and to evaluate the real value of visfatin as
a therapeutical target in the cardiovascular system.
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